Analyst firms · Goldman Sachs · RYTM
Goldman Sachs RYTM price target and rating history
Rhythm Pharmaceuticals Inc. (RYTM) · Health Care
Goldman Sachs rates Rhythm Pharmaceuticals Inc. (RYTM) Buy with a $97 price target, as of its latest action on Jul 10, 2025. It has published 3 rating actions on RYTM since September 2021, including 1 upgrade and 0 downgrades. Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.
- Current rating
- Buy
- Price target
- $97
- Median target, all firms
- $134.50
- Actions on RYTM
- 3
Goldman Sachs price target on RYTM
Every Goldman Sachs rating on RYTM
- Jul 10, 2025
- Aug 8, 2022
- Sep 14, 2021
How other firms rate RYTM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Outperform | Oct 16, 2026 | |
| Wolfe Research | Outperform | Sep 17, 2026 | |
| Leerink Partners | Outperform | $133 | Sep 14, 2026 |
| Deutsche Bank | Hold | $120 | Aug 28, 2026 |
| RBC Capital Markets | Outperform | $478 | Feb 19, 2026 |
| Citigroup | Buy | $136 | Nov 25, 2025 |
Questions about Goldman Sachs and RYTM
- What is Goldman Sachs's price target for RYTM?
- Goldman Sachs's latest stated price target for Rhythm Pharmaceuticals Inc. (RYTM) is $97, from its action on Jul 10, 2025.
- What is Goldman Sachs's rating on RYTM?
- Goldman Sachs rates RYTM Buy, a bullish rating, as of Jul 10, 2025.
- When did Goldman Sachs last change its view on RYTM?
- On Jul 10, 2025, Goldman Sachs starts coverage at Buy, price target $97.
- How does Goldman Sachs's RYTM target compare with other analysts?
- Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.
More RYTM rating histories
All Goldman Sachs ratingsRYTM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.